HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Poshé nail care removes phthalates

This article was originally published in The Rose Sheet

Executive Summary

Nail and hand treatment brand Poshé has removed phthalates from its Anti-Microbial BaseCoat product, parent company Almell Products, Ltd. announces March 4. Phthalates, used as plasticizers in nail products, are potentially harmful, the company claims. The formula is toluene- and formaldehyde-free and is not tested on animals, firm says. "We created the Anti-Microbial BaseCoat to give our clients effective relief for problem nails, and now we've made it phthalate-free," Poshé COO Lynn Beaurline says in a statement. Anti-Microbial BaseCoat is utilized along with Anti-Microbial Cuticle Oil during a pedicure or manicure to prevent growth of mold, fungus, bacteria or yeast on nails and surrounding tissue. BaseCoat retails for $13.20 at Sally Beauty and other beauty supply stores...

You may also be interested in...



Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

UsernamePublicRestriction

Register

RS015294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel